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In recent times, increased attention has been given to evaluating the efﬁcacy of phage
therapy, especially in scenarios where the bacterial infectious agent of interest is highly
antibiotic resistant. In this regard, phage therapy is especially applicable to infections
caused by theBurkholderia cepacia complex (BCC) sincemembers of theBCC are antibiotic
pan-resistant. Current studies in BCC phage therapy are unique from many other avenues
of phage therapy research in that the investigation is not only comprised of phage isola-
tion, in vitro phage characterization and assessment of in vivo infection model efﬁcacy, but
also adapting aerosol drug delivery techniques to aerosol phage formulation delivery and
storage.
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INTRODUCTION
The Burkholderia cepacia complex (BCC) is a group of 17
genetically diverse, but phenotypically similar Gram-negative
rod-shaped bacteria (Papaleo et al., 2010). These opportunis-
tic pathogens are medically signiﬁcant, as they cause respiratory
infections in cystic ﬁbrosis (CF) patients. BCC infections can sig-
niﬁcantly reduce the life expectancy of CF patients and in severe
cases can lead to “cepacia syndrome,” which is characterized by
rapid deterioration of pulmonary function (Isles et al., 1984).
BCC infections are difﬁcult to treat because they are highly antibi-
otic resistant,making alternative treatments such as phage therapy
attractive. Phage therapy utilizes bacteriophages (phages), viruses
that speciﬁcally target particular species of bacteria, to combat
the infection. This review outlines the origins of phage therapy as
well as highlights current research applicable to phage therapy for
combating BCC infections.
DISCOVERY OF PHAGES AND BEGINNINGS OF PHAGE
THERAPY
Bacteriophages were discovered independently by Twort (1915) at
Browns Veterinary Hospital in London and by d’Herelle (1917)
at the Institut Pasteur in Paris. Phages are viruses that exclu-
sively attack and lyse a bacteria (often of a particular species or
strain), which prompted D’Herelle to develop the term “bacte-
riophage,” meaning “bacteria-eater” (d’Herelle, 1917; Bradbury,
2004). Shortly after the discovery of phages, d’Herelle proposed
using them as a possible method of combating infection and
used phages to treat patients with dysentery, bubonic plague, and
cholera with some success. Although there were reports of suc-
cessful phage treatment, not all phage therapy testing was effective.
These variable results were most likely due to a lack of knowledge
in the area of phage biology, a lack of understanding regarding
phage speciﬁcity, the use of phage to treat conditions not caused
by a bacterial infection, improper phage preparation leading to
phage inactivation, and an inability to produce high volumes of
puriﬁed phage (reviewed in Sulakvelidze and Morris, 2001; Brad-
bury, 2004). The discovery of chemical antibiotics, combined with
a perceived inconsistency in phage therapy performance, led to the
discontinuation of phage therapy in the West by the 1940s (Merril
et al., 2003).
CLINICAL USES AND CURRENT EVALUATION OF PHAGE
THERAPY
In Eastern Europe, particularly Georgia, phage therapy research
has continued at the Eliava Institute. During the Soviet Era, the Eli-
ava Institute was responsible for producing phage preparations for
both prophylactic uses as well as for the treatment of infections in
patients across the Soviet Union. The Eliava Institute has reported
many successes, treating patients with a wide range of infections
including skin wounds, and eye, respiratory, and gastrointestinal
infections (Sulakvelidze and Morris, 2001). Unfortunately, these
reports are anecdotal in nature and have rarely been published in
scientiﬁc literature, especially in the English language. With the
advent of antibiotic resistant infections and an improved knowl-
edge of phage biology and bacterial identiﬁcation, phage therapy
is now being revisited by researchers in the West.
Current evaluation of phage therapy is often performed using
animal models, as phage therapy must be proven with controlled
studies before its efﬁcacy in a clinical setting can be evaluated. One
of the most commonly used animal models is the mouse. Mice are
an attractive animal model for many reasons. From a practical
standpoint, their small size and low maintenance costs allow for
comprehensive studies with many subjects (Nadithe et al., 2003).
Mice have been well-characterized and their immune systems have
similarities to the human immune system (Nadithe et al., 2003).
The applications of phage therapy are numerous and many of
these have been and are currently being evaluated, including the
treatment of thermal injury infection (McVay et al., 2007; Kumari
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et al., 2009) and systemic infections (Cerveny et al., 2002; Cap-
parelli et al., 2007), including those that are antibiotic resistant
(Biswas et al., 2002). The applications of phage therapy in vet-
erinary medicine are also being assessed. There is an increased
interest in ﬁnding alternatives to antibiotics for use in animal hus-
bandry as more restrictive regulations against antibiotic use in
livestock and fowl are put in place (Johnson et al., 2008). Such
research has included the evaluation of treating enterotoxigenic
Escherichia coli infections in pigs, calves, and lambs (Smith and
Huggins, 1983) and airsacculitis in chickens (Huff et al., 2002).
Recently, three studies (Merabishvili et al., 2009; Rhoads et al.,
2009; Wright et al., 2009) have either outlined the steps required
to produce a phage preparation useful in clinical studies or eval-
uated phage therapy in controlled human studies. Merabishvili
et al. (2009) outline the production and quality control meth-
ods required to produce a cocktail of Pseudomonas aeruginosa
and Staphylococcus aureus phages (BFC-1) for use in burn wound
infections. At the time of press, BFC-1 had been tested on eight
patientswithno reported adverse effects (Merabishvili et al., 2009).
Rhoads et al. (2009) completed a phase I trial evaluating the
safety of WPP-201, a phage cocktail active against P. aeruginosa,
S. aureus, and E. coli, when applied to venous leg ulcers. This
study did not evaluate the efﬁcacy of the phages, but demon-
strated the safety of WPP-201 with no signiﬁcant difference in
the adverse side effects reported in comparison to the control
group. Wright et al. (2009) evaluated the efﬁcacy of treating
chronic otitis caused by antibiotic resistant P. aeruginosa in a phase
I/II clinical trial. Patients were given a single treatment of either
a placebo or Biophage-PA, a cocktail of six phages, and moni-
tored for 42 days. The Biophage-PA treated group saw signiﬁcant
clinical improvement, and phage activity was retained on aver-
age for 23 days after application. The safety of the product was
also demonstrated in that no adverse side effects were reported
that could be attributed to the treatment. This phage cocktail
should be further evaluated in phase III clinical trials (AmpliPhi,
2011).
MECHANISMS OF PHAGE INFECTION AND PHAGE THERAPY
The main principle upon which phage therapy rests is that after
replication within a bacterium, phages lyse and kill their host cell.
The best candidates for phage therapy are lytic phages (Skurnik
and Strauch, 2006). The basic steps of lytic phage infection for
phages of the order Caudovirales (composed of three families
of tailed phages: Siphoviridae, Myoviridae, and Podoviridae) are
as follows (Figure 1): First, a phage binds to a receptor on the
surface of a bacterium. On a Gram-negative bacterium, phage
receptors can include lipopolysaccharide (both smooth and rough
types) and outer membrane components such as porins, trans-
port proteins, enzymes, and structural proteins (Rakhuba et al.,
2010). Phage interaction with a surface receptor may be enhanced
through the production of a phage-associated enzyme capable of
degrading exopolysaccharide or bioﬁlm components. Once bound
to the receptor, the phage injects its nucleic acid into the bacter-
ial host. The phage early genes are expressed, disrupting bacterial
systems and inducing replication of the phage genome. Late phage
genes are then expressed, allowing production of proteins required
for phage assembly and host lysis. Finally, mature phage particles
are assembled and the host is lysed, causing release of the newly
assembled phages (Skurnik and Strauch, 2006).
Some phages are capable of a temperate or lysogenic lifestyle
in which they integrate into the host genome or exist as a plasmid
and remain dormant, simply being replicated along with nor-
mal bacterial cell division. Such phages will remain in this state
until conditions trigger the phage to enter a lytic lifecycle. This
dormancy can be problematic when using phages in a phage ther-
apy strategy because additional new phages are not being released
(Kropinski, 2006). Temperate phages are also not optimal candi-
dates for phage therapy because they do not cause the rapid host
death required for effective phage therapy treatment (Skurnik and
Strauch, 2006). Additional concerns include lysogenic conversion,
superinfection immunity, and transduction. Lysogenic conversion
is the utilization of prophage genes by the host which may ren-
der the host more virulent than prior to infection. Superinfection
immunity may develop in situations where the host cell becomes
resistant to subsequent infection by a similar phage. Finally, trans-
ductionoccurswhenbacterialDNA(possibly containing virulence
factor genes) is packaged into the phage capsid and transferred to a
new host via the phage (reviewed by Lynch et al., 2010a). Although
lytic phages remain the optimal choice for phage therapy, in sit-
uations where the use of lytic phages is not possible, the efﬁcacy
of phage therapy using temperate (or putatively temperate) viri-
ons has also been demonstrated (Capparelli et al., 2007; Seed and
Dennis, 2009; Carmody et al., 2010; Lynch et al., 2010a; Paul et al.,
2011).
There are three basic steps in treating a clinical infection with
phage therapy. First, the cause of the infectionmust be isolated and
characterized in order to assess strain sensitivity. Second, a phage
preparation must be chosen that is active against the appropri-
ate host. Preferably, the preparation will be a high titer cocktail
of phages with different host receptors, thereby increasing the
activity of the preparation. Finally, the treatment must be appro-
priately administered to the patient according to the location of
the infection (Bradbury, 2004). Many different methods of phage
administrationhave beendescribed in the literature including oral,
rectal, topical, intravenous, and via an aerosol (Sulakvelidze and
Morris, 2001).
The pharmacokinetics of phage therapy are quite different from
any drug currently employed. With a chemical drug, the con-
centration decreases after administration. The opposite is true of
phage. After the originally administered phage replicate, they pro-
vide an increasing phage dose that will continue until the infection
is cleared. This phenomenon is known as active phage therapy
(Payne and Jansen, 2003). Passive phage therapy is also possible if
the initial phage dose is high enough to clear the infection without
phage replication (Payne and Jansen, 2003). Although the con-
cept of active phage therapy suggests that a low phage titer is all
that is required for successful treatment, this is not necessarily the
case. Using a mathematical model simulating the pharmacokinet-
ics of phage therapy, Payne and Jansen (2003) demonstrated that
selecting the correct phage concentration required for successful
treatment should be based on the bacterial density of the infec-
tion. A sufﬁciently dense bacterial community will allow for active
phage therapy. However, a less dense population will not be able to
support active phage therapy because the phage will not be able to
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FIGURE 1 | A phage cocktail is delivered via an aerosol to the site of the
infection where the phage life cycle can be established. First, phage
attach to receptors on the host. (Phage may need to degrade
exopolysaccharide [EPS] in order to reach the phage receptor). After binding,
the phage are able to transfer their nucleic acid into the host. Host systems
are disrupted and the replication of the phage genome begins. Once mature
phage particles have been assembled, the host is lysed and the phages are
released.
reproduce quickly enough to yield and maintain the high in vivo
concentrations required to sustain a high bacterial kill rate. In situ-
ations like this,multiple high titer phage treatments, administered
with a similar schedule to antibiotic therapy, would be required in
order to completely eliminate the infection (Levin and Bull, 2004).
In addition to titer, timing in phage administration is crit-
ical. Using mathematical modeling, Payne and Jansen (2003)
demonstrated that a delay in treatment would prove detrimen-
tal to combating an infection. These modeled data have also been
demonstrated in a mouse model (Cerveny et al., 2002). Interest-
ingly, Payne and Jansen (2003) also demonstrated that a treatment
delivered too early may be detrimental to clearing of the infec-
tion. This detrimental effect is related to low bacterial density.
Sparse bacterial densities, in which the probability of a phage
encountering a bacterial host is low, do not lend themselves to sus-
tainable active phage therapy. If treatment is delayed until active
phage therapy is possible, it will likely be more effective.
ADVANTAGES OF PHAGE THERAPY
Although there are some concerns regarding phage therapy (see
below), there are a large number of potentially positive aspects
to phage therapy as well. Phages are active against bacterial cells
using completely different mechanisms than classical antibiotics,
allowing them to be active against antibiotic resistant bacteria
(Bradbury, 2004). Phage activity against antibiotic resistant bac-
terial strains is likely the most promising feature of phage therapy,
as phages can be used in instances where antibiotic treatment
is no longer possible. Phages have many positive qualities as
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Table 1 | A comparison of some of the main advantages and
disadvantages of antibiotics and phage therapy.
Antibiotics Phage therapy
Speciﬁcity Broad spectrum,
affecting more than the
targeted organism
Generally species or strain
speciﬁc
Side effects Many, including
allergies and intestinal
disorders
No side effects (Bruttin and
Brüssow, 2005; Merabishvili
et al., 2009; Rhoads et al.,
2009; Wright et al., 2009)
Resistance Occurs and is not
limited to targeted
bacteria
Occurs, but can be linked
to host virulence attenuation
(Zahid et al., 2008). Also,




antimicrobials, as shown in Table 1. In direct contrast to antibi-
otics, which are often broad spectrum, phages show more host
speciﬁcity, and in most cases show speciﬁcity to a single species or
strain of bacteria. Using phages would allow for the treatment of
an infection without harming the natural microﬂora of a patient
(Mattey and Spencer, 2008). Phages do not cause negative side
effects to patients, as demonstrated in a study in which human
volunteers drank water containing the E. coli phage T4 (Bruttin
and Brüssow, 2005). In this study there were no reported adverse
affects caused by the phage, as well as no T4-speciﬁc immune
response in the volunteers. These three key features demonstrate
phage therapy’s potential as an effective tool in combating bacterial
infections.
CHALLENGES OF PHAGE THERAPY
The speciﬁcity of phages, which is certainly an advantage, can
also provide one of the challenges that must be overcome when
using phage therapy as a treatment method. Before an infection
can be treated, the causative agent must be characterized or typed
in order to ensure that the correct phage is being used for its
treatment. Strain characterization can be time-consuming and is
especially troublesome in cases that must be treated rapidly. In
order to overcome such problems, phage cocktails can be devel-
oped that are active against a broad range of strains or even
different bacterial species (Levin and Bull, 2004). A potentially
serious complication to phage therapy that must be taken into
consideration is that bacterial strains can develop phage resis-
tance or semi-resistance. Phage resistance may pose signiﬁcant
problems, especially if a phage must undergo rigorous and time-
consuming testing before it is approved for clinical use (Mattey
and Spencer, 2008). In some situations, partial phage resistance
can occur. Although phage can still infect semi-resistant bacteria,
their infection rate is far lower than in sensitive bacteria, rendering
phage therapy less effective (Levin andBull, 2004). Semi-resistance
is most often seen in mucoid colonies, as the mucoid barrier
provides an additional obstacle to phage contacting the appro-
priate receptor. Phage resistance generally occurs by a mutation
in the receptor to which the phage binds. Unlike semi-resistant
bacteria, receptor mutations prevent phages from binding to the
cell, thereby preventing the initial step in phage infection. Phage
resistance and semi-resistance can be minimized by treating infec-
tions with a phage cocktail containing a mixture of phages that
will target different binding receptors on the bacterial cell. This
allows the cocktail to be effective, even if a receptor is altered.
Interestingly, receptor mutation leading to phage resistance may
not always be a bad thing. In some instances, bacteria that develop
phage resistance are also less competitive and less virulent, or even
avirulent. This phenomenon is most noticeable in phage resis-
tant bacteria where the phage receptor lost is a capsule or other
virulence factor (Levin and Bull, 2004), as was demonstrated by
Zahid et al. (2008) who found that Vibrio cholerae cultured with
phage in a nutrient medium quickly became phage resistant, but
also lost their O1 antigen. Another form of resistance that must
be considered is restriction endonuclease resistance. In this case,
the bacterium encodes restriction endonucleases active against the
phage genome, causing destruction of the phage’s genetic material
and inhibiting phage replication. Although restriction endonucle-
ases must be taken into consideration, it may not be of signiﬁcant
importance as many phages are able to evade restriction (Levin
and Bull, 2004).
Phage therapy critics have suggested that the presence of clus-
tered regularly interspaced short palindromic repeats (CRISPR) in
40% of sequenced bacterial genomes is a detriment to phage ther-
apy. Brieﬂy,CRISPRs are genomic sequences of alternating spacers
and palindromic repeats. The spacers are sequences of phage or
plasmid DNA that the host had previously obtained. Identical
matches between the spacers and foreign DNA entering the cell
alert the bacterium to the presence of a potential predator, which
triggers the degradation of the foreign DNA. CRISPRs have been
reviewed in further detail by Horvath and Barrangou (2010). It
should be noted, however, that if the phage has even a single point
mutation in the sequence to be matched to the CRISPR sequence,
the phage will be able to evade the CRISPR system and proceed
with host infection. Additionally, CRISPRs are not a pressing con-
cern in regards to BCC phage therapy as only one of the analyzed
BCC species (B. ambifaria AMMD) contains a conﬁrmed CRISPR
locus (Grissa et al., 2007).
PHAGE THERAPY IN THE BCC
EARLY BCC PHAGE RESEARCH
Research into phages infecting and lysogenizing BCC species is
a relatively recent endeavor, particularly when compared to the
almost century of work related to Enterobacteriaceae phages. The
goal of early BCC phage studies was not to identify phage therapy
candidates, but instead to isolate generalized transducing phages
that could be used for the genetic manipulation of BCC strains
(Cihlar et al., 1978; Matsumoto et al., 1986; Nzula et al., 2000).
Cihlar et al. (1978) were the ﬁrst to publish a description of a
BCC phage in 1978 (Bcep781 was also isolated in 1978, but its
sequence was not published until 2006; Summer et al., 2006). This
group identiﬁed a temperate phage of P. cepacia 249 (now B. mul-
tivorans ATCC 17616) named CP1. This myovirus could infect P.
cepacia 104, 382, and 383 (now B. cepacia ATCC 17478, B. cepacia
ATCC 17759, and B. lata ATCC 17760, respectively), but not 249.
Host range mutants of CP1 were able to infect P. pickettii 472 (now
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Ralstonia pickettii), but not P. aeruginosa,P. ﬂuorescens, or P. phase-
olicola (now P. syringae pathovar phaseolicola). Matsumoto et al.
(1986) were the second group to characterize a BCC phage and
the ﬁrst to identify one capable of generalized transduction. CP75
is a temperate phage of P. cepacia PCT1, an uncharacterized clini-
cal isolate. This myovirus has a∼52 kbp genome and a broad host
range, infecting 46 out of 105 P. cepacia strains screened (although
the identity and relatedness of these strains were not discussed).
More recently,Nzula et al. (2000) identiﬁed two generalized trans-
ducing phages,NS1 andNS2. These are∼48 kbp temperate phages
of B. vietnamiensis ATCC 29424 and B. multivorans ATCC 17616,
respectively. Interestingly, both CP1 and NS2 (in addition to KS5,
discussed below) are temperate myoviruses of ATCC 17616, but
they were found to have differing generalized transduction efﬁ-
ciencies and sensitivity to chloroform (Cihlar et al., 1978; Nzula
et al., 2000). Similar to KS5, both NS1 and NS2 are predicted to
use LPS as a receptor (Nzula et al., 2000; Lynch et al., 2010a).
NS1 and NS2 can infect strains with different serotypes, which
may be a result of minimal phage interaction with the O-antigen
or changes in the strains that were screened (Kenna et al., 2003).
These phages also have a broad host range, particularly NS2: each
could infect strains of B. cepacia, B. multivorans, B. cenocepacia,
B. vietnamiensis, and P. aeruginosa (Nzula et al., 2000). Certain
BCC strains were also found to be susceptible to infection by P.
aeruginosa phages, speciﬁcally E79, B3, F116L, and G101. While
phages that infect both BCC and Pseudomonas strains may be
extremely useful with respect to phage therapy development, it
remains a concern that generalized transducing phages with such
a broad host range could facilitate the exchange of virulence genes
between Burkholderia and Pseudomonas (Nzula et al., 2000).
One BCC phage that has been putatively shown to transfer
resistance genes between distinct species is BcP15. BcP15, a tem-
perate siphovirus of the environmental isolate B. cepacia DR11,
was found to infect only Shigella ﬂexneri Pl-35 (a plasmid-cured
isolate of S. ﬂexneri NK1925; Hens et al., 2005, 2006). Putative Pl-
35 lysogens were resistant to co-trimoxazole, trimethoprim, and
erythromycin, and it was suggested that the integrated BcP15DNA
was responsible for this phenotype (Hens et al., 2006). Further
characterization of BcP15, its hosts, and the mechanisms of gene
transfer and resistance are needed in order to assess the possible
clinical signiﬁcance of these results.
CURRENT BCC PHAGE RESEARCH
PHAGE ISOLATION
In order for phage therapy to be a viable alternative treatment for
BCC infections, BCC-speciﬁc phages appropriate for clinical use
must ﬁrst be isolated and/or developed. Selection criteria for such
phages include a broad host range (in particular clinically preva-
lent species and/or strains), an obligately lytic lifestyle, and the
absence of genes encoding potential virulence factors. Full genome
sequencing is required for the most complete characterization of
these traits. To date, one of the major challenges in BCC phage
therapy development has been ﬁnding phages that satisfy all of the
above criteria. Analysis of BCC phages possessing only some of
these characteristics remains an important exercise because it pro-
vides (a) essential data for studying BCC comparative genomics,
(b) potential clues as to the development of BCC virulence, and
(c) candidate phages for phage therapy that ﬁt these criteria more
closely through the use of genetic modiﬁcation.
Twomajor studies describing the isolation of novel BCCphages
were published by Langley et al. (2003) and Seed and Dennis
(2005). Langley et al. (2003) isolated phages from both known
BCC strains (belonging to B. cepacia, B. multivorans, B. cenocepa-
cia, and B. stabilis) and the environment (soil, rhizosphere, and
sediment samples). Many of these phages have broad host ranges,
infectingmultiple BCC species and evenP. aeruginosa orB. gladioli
in some cases. These phages belong to either the Siphoviridae or
the Myoviridae. Similarly, Seed and Dennis (2005) isolated puta-
tively lytic phages from onion soil and temperate phages from B.
multivorans, B. cenocepacia, B. ambifaria, and B. pyrrocinia. These
phages had narrow to broad host ranges within the BCC and in
some cases could infect B. gladioli (but not P. aeruginosa). These
phages also belong to either the Siphoviridae or the Myoviridae.
An issue common to many BCC phage studies is the identiﬁca-
tion and characterization of identical or nearly identical temperate
phages by multiple groups. This issue is best illustrated by phages
BcepMu, DK4, and KS4/KS4-M. BcepMu was isolated and fully
sequenced by Summer et al. (2004). This phage is a 36,748 bp
transposable myovirus found as a prophage in B. cenocepacia
J2315, BC7, C5424, and other B. cenocepacia ET12 strains (exclud-
ing K56-2). BcepMu shows relatedness to transposable phages of
Salmonella typhi (SalMu), Photorhabdus luminescens (PhotoMu),
andChromobacterium violaceum (ChromoMu). DK4, isolated and
described by Langley et al. (2003) as a temperate phage of J2315,
was later identiﬁed as BcepMu based on sequencing of PCR ampli-
cons and RFLP analysis (Langley et al., 2005). Like BcepMu, KS4
was isolated from a culture of J2315 and propagated on K56-2
(Seed andDennis,2005). Repeatedpassage in broth culture yielded
a liquid-clearing variant of this phage named KS4-M (Seed and
Dennis, 2009). Despite its temperate nature, this phage may be
a candidate for clinical use as it has been shown to be (a) active
against K56-2 in vivo and (b) stable during nebulization, freeze-
drying/lyophilization, and spray-drying (as discussed below; Gol-
shahi et al., 2008, 2011; Seed and Dennis, 2009; Matinkhoo et al.,
2011). As phage characteristics such as host range and appar-
ent virion dimensions may be recorded differently among various
research groups, the determination of partial or complete genome




Although most of the following studies are only peripherally
related to phage genomics, they provide a wealth of information
regarding the distribution of prophages in BCC genomes and their
patterns of expression under different environmental conditions.
Burkholderia multivorans
Using in vivo expression technology (IVET), Nishiyama et al.
(2010) examined the expression of B. multivorans ATCC 17616
genes in soil. They found that several phage genes were induced
under these conditions, including BMULJ_03661–03667 (KS5
genes 21–27, encoding a translational regulator and tail morpho-
genesis proteins). In that sameyear,Ronning et al. (2010) identiﬁed
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putative prophage regions in several Burkholderia species, includ-
ing B. multivorans. These included two regions in B. multivorans
CGD1, three regions in B. multivorans CGD2, and three regions
in ATCC 17616 [including those containing Bcep176 (PI 17616-3)
and KS5 (PI 17616-4)].
Burkholderia cenocepacia
To identify genomic differences between the highly pathogenic B.
cenocepacia and other less pathogenic BCC species, Bernier and
Sokol (2005) used suppression-subtractive hybridization with B.
multivorans C5393, B. cenocepacia K56-2, and B. stabilis LMG
14294. Several putative phage or phage-related genes were iden-
tiﬁed that were unique to B. cenocepacia. When the complete
genome sequence of J2315 was published in 2009, at least ﬁve
prophages were identiﬁed: BcenGI1 (25.0 kbp) and BcenGI7
(37.7 kbp; KS10) on chromosome 1, BcenGI12 (46.8 kbp) and
BcenGI13 (46.2 kbp) on chromosome 2, and BcenGI14 (36.7 kbp;
BcepMu) on chromosome 3 (Holden et al., 2009). BcenGI7 (dis-
cussed below) and BcenGI14 (discussed above) have also been
sequenced independently of J2315 (Summer et al., 2004; Goudie
et al., 2008). Two studies proﬁling the transcription patterns
of B. cenocepacia strains under different conditions have iden-
tiﬁed prophage genes as part of their analysis. O’Grady et al.
(2009) collected microarray data for stationary phase B. cenocepa-
cia K56-2 quorum sensing mutants (cepR, cciR, and cepRcciIR)
and found that 24, 5, and 20 phage genes, respectively, had dif-
ferent expression in the mutants compared to wild type K56-2.
Many of these genes corresponded to BcenGI12. When Peeters
et al. (2010) exposed J2315 bioﬁlms to hydrogen peroxide for
extended periods (30–60min) and then performed microarray
analysis, they observed increased gene expression from BcenGI14
(speciﬁcally the region containingBcepMugenes 1–16),with some
genes showing an increase in expression greater than 10-fold as
compared to unstressed bioﬁlm cells not treated with hydrogen
peroxide.
WHOLE PHAGE ANALYSIS
Although there are many BCC phages with sequences that have
been deposited into GenBank, this review will focus on those that
are both in the database and published. All BCC phages sequenced
to date belong to the orderCaudovirales, containing the three fami-
lies of tailed phages: Siphoviridae (with long non-contractile tails),
Myoviridae (with contractile tails), and Podoviridae (with short
non-contractile tails; Ackermann, 2001).
Siphoviridae
The only BCC siphovirus sequence published to date is that of
KS9, a 39,896 bp temperate phage of B. pyrrocinia LMG 21824
(Seed and Dennis, 2005; Lynch et al., 2010a). This phage is most
closely related to the temperate phages φE125 of B. thailandensis
and φ1026b of B. pseudomallei and to a prophage element in B.
cenocepacia PC184. KS9-lysogenized K56-2 is no more virulent
in the Galleria mellonella model than wild type K56-2, suggesting
that this phage does not increase host virulence. This phage was
used in a proof-of-principle experiment (Lynch et al., 2010a) to
show that stable lysogeny could be prevented by knocking out the
phage repressor gene, thus making the phage a better candidate
for clinical use.
Myoviridae
Summer et al. (2006) published the ﬁrst and thus far only
genomic characterization of obligately lytic BCC phages isolated
from the environment: myoviruses BcepB1A (47,399 bp), Bcep43
(48,024 bp), Bcep1 (48,177 bp), and Bcep781 (48,247 bp). These
phages have narrow host ranges, only infecting one or two BCC
strains each. The latter three phages are very closely related,
with percent identities between 87.4 and 97.6% for pairwise
comparisons.
Similar to BcepMu,Goudie et al. (2008) characterized a second
transposable Mu-like temperate myovirus of B. cenocepacia J2315.
KS10 is 37,635 bp in length and infects B. cenocepacia PC184, B.
stabilis 18870, and B. ambifaria LMG 19467. Like BcepMu, it has a
relatively wide distribution in B. cenocepacia, lysogenizing K56-2,
J2315, C5424, and seven clinical isolates. Although this distribu-
tion suggests that KS10 may be selected for in B. cenocepacia, it
was not found to encode any proteins that could be considered
virulence factors.
Lynch et al. (2010b) characterized three BCC myoviruses that
belong to the P2-like phage genus. Although all of these phages are
temperate, theywere isolated fromboth BCC cultures and/or envi-
ronmental samples. Their genome size range is broad: 32,317 bp
for KS14, 37,236 bp for KS5, and 40,555 bp for KL3. These phages
encode a number of interesting features, including an insertion
sequence and reverse transcriptase in KS5 and aDNAmethylation,
restriction, and repair module in KL3. Phages KL3 and KS5 were
found to integrate as prophages into a threonine tRNA gene and
an AMP nucleosidase gene, respectively. KS14 has been shown to
be active in vivo and is stable upon spray drying (Seed and Dennis,
2009; Matinkhoo et al., 2011).
Podoviridae
The only BCC podovirus sequences published to date, Bcep22
(63,882 bp) and BcepIL02 (62,714 bp), are closely related and
belong to a single recently identiﬁed phage type: the Bcep22-like
phages (Gill et al., 2011). Both phages encode multiple copies of
their tail ﬁber proteins (four for BcepIL02 and three for Bcep22)
and a large protein of∼4600 amino acids with soluble lytic transg-
lycosylase, helicase, and methylase domains. Although BcepIL02 –
which has been shown to be active in vivo – was initially thought
to be lytic, it was found that both of these phages encode proteins
for integration but cannot form stable lysogens (Carmody et al.,
2010; Gill et al., 2011). BcepIL02 carries a putative lipid A mod-
iﬁcation gene which may modulate bacterial host virulence. The
presence of such a gene in BCC phages is rare (an obvious advan-
tage for the development of phage therapy), as the only other
sequenced BCC phage with a putative virulence gene is BcepMu
(Summer et al., 2004). It has been suggested that bacterial viru-
lence genes are not frequently found in the BCC phage population
because BCC bacteria are not classical bacterial pathogens, but
inhabitants of both the environment and immunocompromised
individuals (Summer et al., 2007). A manuscript describing DC1,
a third Bcep22-like phage with a relatively broad host range, is
currently in press (Lynch et al., in press).
AEROSOL PHAGE DELIVERY
Although aerosol phage therapy has not been reported in the
literature a great deal, it remains a popular option for treating
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respiratory infections and many of the techniques used for aerosol
drug delivery are being adapted to phage therapy. Aerosol drug
delivery has been successfully employed for many pharmaceuticals
including bronchodilators, antibiotics, mucolytics, and anesthet-
ics (Heslop and Harkawat, 2000), as it enables a drug to reach the
diseased site rapidly and requires lower doses of medication than
other delivery methods (Thorsson and Geller, 2005). As phages
require direct contact with their bacterial hosts in order to be
active, aerosol phage delivery appears to be a logical method of
delivering phages rapidly to the site of a pulmonary infection.
There are many aspects of aerosol phage therapy to be evalu-
ated in order to ensure that it can be used as a reliable treatment
method. These research areas include phage preparation, storage,
and delivery methods, as well as demonstration of activity in vitro
and effective treatment of an infection in vivo.
CLINICAL TREATMENT USING INHALATION PHAGE THERAPY
There are three case studies that mention the use of inhalation
phage therapy as a clinical treatment method. Unfortunately, one
of these papers is not written in English and therefore is dif-
ﬁcult to review (Garsevanishvili, 1974). The other two papers
(Hoeﬂmayr, 1963; Kutateladze and Adamia, 2008) are case studies
describing the treatment and recovery rates of patients treated by
inhalation phage therapy. Although these studies do not directly
address the treatment of BCC infections, they are still of interest
because they outline situations in which aerosol phage therapy
has been employed in the past. The ﬁrst clinical study (Hoe-
ﬂmayr, 1963) evaluated the recovery of 29 respiratory infection
patients treated by an aerosolized phage cocktail. The patients
were chosen because they could not be treated by conventional
methods such as expectorant, secretolytic, or antibiotic therapies.
Approximately two-thirds of the patients had Streptococcus infec-
tions, while the remaining patients had Staphylococcus infections.
The phage cocktail used was Diriphagen, a commercially available
cocktail containing 180–200 phages speciﬁc for different bacte-
rial species. In addition to phage, Diriphagen also contained an
“aimed antimicrobic,”which targeted bacterial strains that became
phage resistant during the course of the treatment. No mention
was made as to what this aimed antimicrobic was or how it func-
tioned. This particular phage cocktail was chosen because of the
large number of different phages it contained. During the course
of the study, the patients received daily aerosolized phage treat-
ments. The treatments lasted 10–15min. The average number of
treatments per patient was 11, while some patients received as
few as three treatments and one patient received as many as 40
treatments. After treatment, the symptoms of the 29 patients were
classed into three groups: 55% were reported to have made a com-
plete recovery, 35% showed considerable improvements and 10%
showed no change. When the bacterial load in the sputum cul-
tures was determined, it yielded contradictory results. All patients
had detectable levels of either Staphylococcus or Streptococcus, with
30% of the patients showing considerable improvement, 55%
showing some improvement and 10% showing no improvement.
Interestingly, at least one patient showed no change in symptoms.
However, her bacterial counts decreased substantially. Unfortu-
nately, there weremany aspects of this study that were not properly
described or quantiﬁed. Therewas no information given as towhat
exact infection each of the patients had (as it was not uniform
throughout the group), making it difﬁcult to determine if the
phage cocktail was more effective against certain species or strains.
No mention was made of what criteria were given to class the
patients’ symptoms as “considerably improved” and neither were
there values associated with a “considerable decrease” or “some
decrease” in bacterial load in the sputum. This study provides
some anecdotal evidence that phage therapy may be an effective
method of treating respiratory infections, but cannot provide any
conclusive results.
A more recent case study (Kutateladze and Adamia, 2008)
described the treatment of a 5-year-old CF patient at the Eli-
ava Institute in Tbilisi, Georgia. This patient had both S. aureus
and P. aeruginosa respiratory infections that were resistant to
antibiotic treatment. These strains were sensitive to pyophage, a
commercially available phage cocktail active against S. aureus, P.
aeruginosa, Streptococcus, Proteus, and E. coli. The patient com-
pleted a treatment regimen of three multi-day treatments admin-
istered at 1month intervals. During the ﬁrst treatment period,
pyophage was administered by nebulizer daily over a 6-day period.
In addition to the pyophage treatment, the patient received vit-
amins and an antimucosal treatment. After this treatment, the
patient’s condition was described as improved; this characteriza-
tion was based on weight gain (the patient had gained no weight
in the previous year and gained 1 kg after the treatment), facil-
itation of expectoration and lack of sputum. No mention was
made to indicate if the bacterial load in the lungs had changed
after this treatment. A second 10-day treatment was performed a
month after the initial treatment. The concentration of S. aureus
increased while the P. aeruginosa concentration did not change
during this treatment period. The second treatment was not effec-
tive and based on the increase in S. aureus concentration, it was
assumed that the S. aureus had become pyophage resistant. The
third and ﬁnal treatment administered in this case study was a
combination of pyophage and tetracycline. After this treatment
S. aureus and P. aeruginosa could not be detected in the patient.
At the time of publication the patient was still receiving phage
therapy on occasion as respiratory infections were identiﬁed. It
is unfortunate that this particular case study was presented as
an example of successful inhalation phage therapy as the evi-
dence is anecdotal and not particularly convincing. A quantitative
change in respiratory bacterial load before and after the treat-
ments was not reported. Instead, the efﬁcacy of the treatment
was generally evaluated based on the change in patient symp-
toms. The S. aureus and P. aeruginosa strains appeared to become
phage resistant during the second treatment and did not decrease
to undetectable levels until the phage treatment was combined
with antibiotics, suggesting that the antibiotic treatment or the
combination therapy at best, but not the phage therapy alone,
cleared the infection. In order to demonstrate that phage therapy
is an effective medical treatment, full clinical studies with con-
trol groups will be required and this case study emphasizes this
point.
SIMULATED AEROSOL PHAGE DELIVERY TO HUMANS
Methods of aerosol drug delivery are continually evolving and so
it is important to assess these methods with respect to the efﬁcacy
of aerosol phage delivery, ensuring that the phages are delivered
to the location of the infection and also that they are delivered
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intact and able to infect and lyse their host. In treating a respi-
ratory infection, one must ensure that the phage aerosol has the
correct characteristics required to impact into the area of the lung
where the infection resides. Phage liquids can be delivered using
a nebulizer. Two common types of nebulizers in use in a clini-
cal setting are the jet nebulizer, such as the Collison or the LC
Star, and the ultrasonic nebulizer, such as the eFLOW (Golshahi
et al., 2008). The key feature of a nebulizer is that it must generate
particles of the appropriate size to impact in the correct location
within the pulmonary system. The typical particle size generated
by a nebulizer is generally 1–5μm, which allows the aerosol to
reach the smaller bronchioles (Golshahi et al., 2008). One study
has been performed to assess the feasibility of aerosolizing phage
using a nebulizer, which is commonly used for delivering drugs via
an inhalation route (Golshahi et al., 2008). This in vitro method
employed a computer controlled breath simulator to mimic the
natural breathing patterns of an adult. A BCC phage, KS4-M, able
to infect B. cenocepacia strain K56-2 was aerosolized using one
of two commonly used nebulizers: the LC star (a jet nebulizer) or
the eFLOW(an ultrasonic nebulizer). The aerosol size distribution
of the particles was measured as the aerosol exited the nebulizer
using phase Doppler anemometry. A ﬁlter placed in line with the
breath simulator collected the aerosolized phage, allowing for the
quantiﬁcation of phage exiting the nebulizer, which was classiﬁed
in the study as the inhaled phage. The collected phage were quan-
tiﬁed by plating using a soft agar overlay method. As this method
only quantiﬁed viable phage, it only took into account the number
of phage that were able to survive the aerosolization process (and
would therefore theoretically be active within a host). In addition
to enumerating thenumber of phage able to survive aerosolization,
these data were also employed in mathematical models to deter-
mine the regional lung deposition of the phage aerosol based on a
numerical lung deposition model. Using this model, calculations
were performed to compare the phage deposition in the extratho-
racic, tracheobronchial, and alveolar regions of the lung with both
of the nebulizers. The results for both nebulizers were quite similar
suggesting that either class of nebulizer would be effective in gen-
erating phage aerosols. The LC star and eFLOW produced aerosols
with similar properties with mass median diameters of 4.98 and
5.83μm, respectively and geometric standard deviation (the mea-
sure of particle monodispersity) of 1.48 and 1.44μm, respectively.
The inhaled phage concentrations produced by both of the neb-
ulizers was also quite comparable with the LC star aerosolizing
1.06× 108 plaque forming units (PFU) and the eFLOW aerosoliz-
ing 1.15× 108 PFU. There was a one order of magnitude decrease
from the inhaled phage concentration (approximately 108 PFU)
to the predicted concentrations deposited in each of the three
lung areas (approximately 107 PFU) for both of the nebulizers
tested.However, this is still a signiﬁcant phage concentration being
delivered to the lungs and the particle deposition in each region
of the lung was similar in both cases. The results of this study
add credibility to aerosol phage delivery as a potential treatment
method for respiratory infection. While mathematical modeling
provides an indication as to the outcome of an experiment, it is
not a replacement for biological experimental data. This study
serves as an excellent starting point for experimentally deter-




A number of recent studies have been performed to investigate
phage preparation methods for use in phage aerosols, including
lyophilization and spray-drying (Puapermpoonsiri et al., 2009;
Golshahi et al., 2011; Matinkhoo et al., 2011). Freeze-drying and
spray-drying allow thephage stock to be converted to a dry powder,
which is delivered to a patient via an inhaler. Delivering phage as
a powder would be a rather simple method of treating patients. A
dry powderwould also be simpler to handle and easier to transport
than the liquid phage suspension required for nebulization. There
are a number of advantages to dry powder phage preparations
including easier transport and longer-term storage capabilities.
Treatments can be delivered using a dry powder inhaler in a single
breath, making it a faster delivery method than nebulization. A
recent study (Puapermpoonsiri et al., 2009) outlines a method
for lyophilizing (or freeze-drying) and encapsulating phage in
biodegradable poly(dl-lactic-co-glycolic acid) microspheres. The
microspheres canbedelivereddirectly to the lungs via adrypowder
inhaler and have been previously approved for use in humans (Lü
et al., 2009). This proof-of-concept was performed to determine
if phages speciﬁc to S. aureus and P. aeruginosa could be freeze-
dried and disseminated as well as to determine the shelf-life of the
phages after freeze-drying and encapsulation. The microcapsules
were developed for use in a dry powder inhaler. The encapsulation
efﬁciency for S. aureus phage was 18%, while the efﬁciency for
the P. aeruginosa phage was 27%. In dispersion tests, 55% of the
total released contents of the S. aureus phage microcapsules was
released within 30min and release of the phage continued for 6 h.
Similarly, within 30min 63% of the total released P. aeruginosa
phage was dispersed.
Both of the phages tested could survive lyophilization and
remain at high titers for at least 3 days, at 4˚C as well as at
22˚C, which would also allow for easier handling and transport.
However, after 7 days the phages were no longer viable. Unfortu-
nately, the phage titers dropped quickly enough that counts of “too
numerous to count” could not be replated for accurate counts and
had to be reported in a semi-quantitative fashion, so only trends
could be reported. This study demonstrated that freeze-drying
followed by encapsulation intomicrospheres shows promise, espe-
cially as a dispersal technique. However the phages would need to
be further stabilized for increased survivability.
An additional study (Golshahi et al., 2011) took a different
approach to developing phage aerosol powders, formulating pow-
ders for both KS4-M, a BCC phage, and ΦKZ, a P. aeruginosa
phage. Instead of encapsulating the phage powder in a micros-
phere, the endotoxin-removed phage stocks were freeze-dried in
a mixture of carriers that help to stabilize the phage as well as
enhance the dispersibility of the powder. The latter is an important
consideration for the future use of phage powders as a thera-
peutic because dispersibility affects the efﬁcacy with which the
phages will reach the site of infection. Golshahi et al. (2011)
demonstrated that a combination of lactose/lactoferrin 60: 40
w/w was an effective carrier for both phage stability and dis-
persibility. Lactose is an excipient that is currently used in dry
powder inhalers in the United States (Telko and Hickey, 2005),
while lactoferrin was chosen for its effect on particle size as well
as for its antimicrobial properties. The combination of lactoferrin
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and phages has also been previously demonstrated to be more
effective in treating infection in mice than either treatment sepa-
rately (Zimecki et al., 2008). The lyophilization process caused a
reduction in phage titer, with a reduction of two orders of mag-
nitude for KS4-M and one order of magnitude for ΦKZ. This
ﬁnding should not pose a problem for lyophilizing these phages
because both can be grown to a high initial titer. Additionally, in
contrast to freeze-dried, encapsulated phages (Puapermpoonsiri
et al., 2009), both the freeze-dried KS4-M and ΦKZ phages were
able to maintain viability for long periods of time. Both phage
titers remained essentially constant at the same order of mag-
nitude (approximately 108 PFU/100mg) for 3months, regardless
of storage temperature (both 4 and 22˚C were tested). After
a year of storage at 4˚C, ΦKZ remained at 108 PFU/100mg
while KS4-M dropped to 107 PFU/100mg. Even at 22˚C ΦKZ
fared well with the titer remaining at 107 PFU/100mg, while
KS4-M dropped to 102 PFU/100mg (unpublished results). This
lyophilization method shows great promise for long-term phage
storage. In addition to testing phage stability, the phage powders
were tested in a commercially available Aerolizer® dry powder
inhaler. When attached to a mouth–throat replica known as the
“Alberta Idealized Geometry,” the efﬁcacy with which the freeze-
dried phages could be delivered to the site of a pulmonary infection
was evaluated. This study also provided promising results with
less than an order of magnitude drop from the phage load in the
inhaler to deposition within the lungs. This study demonstrated
that phage freeze-drying is a viable method of preserving phages
for long-term storage. The powdered phages also show a great
deal of promise as a therapeutic delivery method in aerosol phage
therapy and should be evaluated further.
SPRAY-DRYING
Using a different approach, Matinkhoo et al. (2011) evaluated
spray-drying rather than lyophilization as a method of develop-
ing phage powders. Spray-drying is another method of producing
pharmaceutical powders which has the added advantage of allow-
ing for a greater selection in particle characteristics (Vehring,
2008). As with Golshahi et al. (2011), KS4-M and ΦKZ were
used in the study, but an additional BCC phage, KS14 (discussed
above) was also tested. The spray-drying process was less damag-
ing to the phages than lyophilization with one-half to one order of
magnitude drop in titer for each of the phages, depending on the
excipients used. These ﬁndings show an improvement over the two
orders of magnitude drop in titer after freeze-drying. Although the
long-term viability of the spray-dried phages was not determined
in this study and therefore cannot be compared to freeze-dried
phages, the phage powders were tested in the same mouth–throat
apparatus as the freeze-dried phage in the previously described
study (Golshahi et al., 2011). The spray-dried phages outper-
formed the freeze-dried phages with respect to lung deposition
with two times more spray-dried phage delivered to the lungs in
comparison to the freeze-dried phage. Also, more than 50% of
the total inhaler dose was delivered to the lungs. In comparison,
a survey of 12 commercially available inhalers showed a range of
delivery efﬁciencies from 6 to 41% (Newman and Busse, 2002).
These data demonstrate the plausibility of using spray-drying as
a method of developing phage therapeutics, provided that the
spray-dried phages can remain stable for long periods of time.
PHAGE THERAPY EVALUATION IN VIVO
To date, there are two major in vivo models that have been used
for evaluating phage therapy against BCC infections: the G. mel-
lonella (Greater wax moth) larvae model (Seed and Dennis, 2009;
Lynch et al., 2010a) and the mouse lung infection model (Car-
mody et al., 2010). The G. mellonella larvae infection model is
used to determine the efﬁcacy of phages to rescue infected lar-
vae from death. This model is relatively simple to work with: the
larvae are injected ﬁrst with bacteria, then phage (either imme-
diately after infection or after a set duration) and the percentage
of deaths is then calculated 48 h post-infection. Prior to the use
of G. mellonella as a phage therapy model, the pathogenicity of
23 BCC strains in G. mellonella was compared to pathogenic-
ity in alfalfa seedlings, in rats, and in Caenorhabditis elegans. It
was demonstrated that G. mellonella results are comparable to
those in other in vivo models (Seed and Dennis, 2008). Seed and
Dennis (2009) initially evaluated this model for BCC infections
using two strains of B. cenocepacia, K56-2 and C6433, given at
lethal concentrations. The survival rate of the larvae increased
with increased phage multiplicity of infection (MOI) for KS12. A
decrease in duration between infection and treatment also rescued
more larvae. Using the same model, Lynch et al. (2010a) were able
to compare the efﬁcacy of a genetically modiﬁed lytic phage and
the wild type phage in rescuing infected G. mellonella larvae. Gene
41 of KS9, a temperate phage isolated from B. pyrrocinia LMG
21824, was identiﬁed to putatively encode the phage repressor. By
disrupting the gene, KS9 became a lytic variant (named KS9c).
KS9c was tested in the G. mellonella model to determine if the
conversion from a temperate phage to a lytic phage would allow it
to be a more effective phage therapeutic. Unexpectedly, although
the KS9c variant did not stably lysogenize the bacterial host and
was active in vivo, it performed similarly to the wild type phage
KS9. These results demonstrate the value in having a simple ani-
mal model for testing hypotheses such as the one described. Both
of these papers demonstrate the usefulness of G. mellonella as an
initial test for evaluating the efﬁcacy of a phage against the BCC
in vivo.
The mouse lung infection model involves delivering ﬁrst bac-
teria and then phage to the lungs of mice. The bacterial or phage
suspensions are often delivered intranasally by placing small vol-
umes of liquid on the nares of anesthetizedmice, allowing themice
to inhale the liquid. Intranasal sample delivery is used to mimic
aerosol delivery to a human via a nebulizer. This method was used
for evaluating the use of aerosol phage therapy to treat a BCC
infection (Carmody et al., 2010). In this study, mice were infected
with B. cenocepacia via tracheotomy and 24 h post-infection were
treated with phage BcepIL02 delivered by either intranasal inhala-
tion or intraperitoneal injection. Forty-eight hours after treatment
the mice were euthanized and the lungs assayed for bacterial and
phage titer. Interestingly, the mice that received the intranasal
phage treatment had approximately a oneorder of magnitudedrop
in BCC bacterial load while the mice that received the intraperi-
toneal phage treatment had a two log drop in BCC bacterial
load. Although neither of the described phage delivery meth-
ods produced substantial therapeutic results, the authors suggest
that phages delivered indirectly are more effective than phages
applied directly to the infection site. It should be noted that
although intranasal delivery of liquids to the lung is meant to
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mimic aerosol delivery via a nebulizer, it is not an optimal replace-
ment for actual aerosol delivery in mice. Intranasal delivery in
mice has been demonstrated to be far more variable and less
reproducible than aerosol delivery (Halperin et al., 1988). Addi-
tionally, aerosol particle deposition within the lung was shown to
have improved uniformity in comparison to intranasal delivery.
These data suggest that a study with similar methodologies to that
of Carmody et al. (2010) should be performed using an aerosol
delivery method and the results compared to determine if there
is a difference between intranasal and aerosol phage delivery in
mice.
Although these studies are not directly comparable due to dif-
ferent host–phage interactions, it is interesting to contrast the ﬁnd-
ings of Carmody et al. (2010)with the results found byDebarbieux
et al. (2010) and Morello et al. (2011) when treating P. aeruginosa
respiratory infections in mice. Both studies infected and treated
the mice via intranasal inhalation. Debarbieux et al. (2010) treated
the mice 2, 4, or 6 h post-infection and tracked mortality for 72 h.
At the endpoint, 100% of mice treated 2 h post-infection, 75%
of mice treated 4 h post-infection, and 25% of mice treated 6 h
post-infection survived. The mice treated 2 h post-infection had a
bacterial load six orders of magnitude lower than untreated mice
24 h after treatment. Similarly, Morello et al. (2011) demonstrated
that mice infected with a strain of P. aeruginosa isolated from a CF
patient and treated with a sufﬁciently high MOI 2 h post-infection
and euthanized 20 h post-infection had a reduction in bacterial
load of two orders of magnitude. Interestingly, they were also able
to demonstrate, using immunohistochemistry, that the remaining
bacteria in the treated mice were mainly in the macrophages in
the lungs while the untreated mice had bacteria throughout the
macrophages, alveolae, and extracellular spaces within the lungs.
These ﬁndings indicate that phage therapy was able to work with
the immune system in order to effectively clear the P. aeruginosa
infection. These conﬂicting results between Carmody et al. (2010)
and the results obtained by Debarbieux et al. (2010) and Morello
et al. (2011) demonstrate the necessity for further evaluation of
aerosol phage therapy.
In both P. aeruginosa studies, the effect of phage as a prophy-
lactic was also evaluated. Debarbieux et al. (2010) demonstrated
that phage administered 24 h prior to infection allowed for 100%
survival, while all mice in the control group died within 2 days.
Morello et al. (2011) reported a similar trend with a pretreatment
occurring 4 days prior to infection.Although generally phage ther-
apy is thought of as an infection treatment method, these results
suggest that aerosol phage therapy may also be a useful method
for preventing BCC infection.
CONCLUSION
Aerosol phage therapy and phage therapy against the BCC are
two ﬁelds of study that have not been investigated in great detail
until recently. Through the use of two different in vivo models,
the G. mellonella model and the mouse lung infection model,
phages have recently been demonstrated to be effective against
the BCC. Using a mechanical lung model it was demonstrated
that BCC phages could successfully be delivered to the human
lung, remaining viable after deposition within the lung. Addition-
ally, dry powder aerosol phage delivery appears to be a promising
alternative to liquid phage nebulization. BCC phages have been
successfully freeze-dried and spray-dried and can be successfully
stored and aerosolized after processing. With advancing research,
BCC phage therapy continues to show promise as an alternative
antimicrobial therapy.
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